New hope for liver cancer patients who stop responding to immunotherapy?
NCT ID NCT04588051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabozantinib
- What this could lead to
- If it works, this could offer a new treatment option for liver cancer patients whose disease has worsened after immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The drug may not work or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASAN Medical Center
Seoul, South Korea
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- Epigenetic drug may re-sensitize liver tumors to immunotherapy
- New hope for liver cancer patients who failed immunotherapy?